Successful Outcome Of Phase 3 Studies Of SMLNUD07 - Norudca
26/08/2024 05:35
Aug 26 (Reuters) - Shilpa Medicare Ltd SHME.NS :
* SHILPA MEDICARE LTD- SUCCESSFUL OUTCOME OF PHASE 3 STUDIES
OF
SMLNUD07 - NORUDCA
* SHILPA MEDICARE LTD - TRIAL RESULTED IN SIGNIFICANT, AT
LEAST
ONE STAGE, DECREASE IN LIVER FIBROSIS
* SHILPA MEDICARE LTD - COMPLETED PHASE-3 CLINICAL STUDIES
OF ITS
NOVEL PRODUCT SMLNUD07
* SHILPA MEDICARE LTD - THERE WAS A SIGNIFICANT REDUCTION IN
FAT
ACCUMULATION IN LIVER
* SHILPA MEDICARE LTD - PLANS TO SUBMIT THESE PHASE 3
CLINICAL
TRIAL FINDINGS AT EARLIEST TO CDSCO
Source text for Eikon: ID:nBSE8DmCB9
Further company coverage: SHME.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026